UBE2R2

Across TCGA pan-cancer cohorts, UBE2R2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of UBE2R2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where UBE2R2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2R2 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

LUAD, PDAC, and LSCC are the cancer types where UBE2R2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2R2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.197	<.001	9	view →
PDAC	Female	III,IV	−0.700	.004	5	view →
LSCC	Male	All	+0.191	<.001	4	view →
HNSC	Male	II,III,IV	−0.139	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

UBE2R2–LUAD

Open the LUAD breakdown →